Ocular Inflammation and Pain After Cataract Surgery
Ophthalmology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Formosa PharmaceuticalsTaiwan - Taipei
2 programs1
1
APP13007, 0.05%Phase 31 trial
APP13007, 0.05%Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Formosa PharmaceuticalsAPP13007, 0.05%
Formosa PharmaceuticalsAPP13007, 0.05%
Clinical Trials (2)
Total enrollment: 535 patients across 2 trials
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
Start: Mar 2021Est. completion: Jul 2022370 patients
Phase 3Completed
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
Start: Aug 2019Est. completion: Apr 2020165 patients
Phase 2Completed
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
10h ago
Cleanroom and Laboratory Technician
SAB BIO
10h ago
Material Handler - 8 Hour Day Shift
Pfizer
United States - Kansas - McPherson
Yesterday
Senior Process Technician - Rotating 2nd Shift
Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr
Staff Equipment and Systems Engineer
Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space